Cargando…

Probiotics modulate gastrointestinal microbiota after Helicobacter pylori eradication: A multicenter randomized double-blind placebo-controlled trial

BACKGROUND: Helicobacter pylori (H. pylori) eradication has been reported to cause short-term disruption of gut microbiota. It is acknowledged that probiotics supplementation mitigates side effects induced by H. pylori eradication, yet its role on alleviating dysbiosis of microbiota is obscure. OBJE...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Cong, Xie, Yong, Zhu, Yin, Zhuang, Kun, Huo, Lijuan, Yu, Yong, Guo, Qiang, Shu, Xu, Xiong, Zhijuan, Zhang, Zhenyu, Lyu, Bin, Lu, Nonghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679295/
https://www.ncbi.nlm.nih.gov/pubmed/36426355
http://dx.doi.org/10.3389/fimmu.2022.1033063
_version_ 1784834160643276800
author He, Cong
Xie, Yong
Zhu, Yin
Zhuang, Kun
Huo, Lijuan
Yu, Yong
Guo, Qiang
Shu, Xu
Xiong, Zhijuan
Zhang, Zhenyu
Lyu, Bin
Lu, Nonghua
author_facet He, Cong
Xie, Yong
Zhu, Yin
Zhuang, Kun
Huo, Lijuan
Yu, Yong
Guo, Qiang
Shu, Xu
Xiong, Zhijuan
Zhang, Zhenyu
Lyu, Bin
Lu, Nonghua
author_sort He, Cong
collection PubMed
description BACKGROUND: Helicobacter pylori (H. pylori) eradication has been reported to cause short-term disruption of gut microbiota. It is acknowledged that probiotics supplementation mitigates side effects induced by H. pylori eradication, yet its role on alleviating dysbiosis of microbiota is obscure. OBJECTIVES: To evaluate the impact of probiotics on gastrointestinal microbiota after eradication therapy. METHODS: This was a multicenter, double-blinded, randomized trial done at seven centers in China. A total of 276 treatment-naïve H. pylori-positive patients were randomly assigned to receive 14-day bismuth-containing quadruple therapy (esomeprazole, bismuth, amoxicillin, furazolidone) combined with probiotics (Bifidobacterium Tetragenous viable Bacteria Tablets) (n=140) or placebo (n=136) for 28 days. Saliva, gastric mucosa and fecal samples were collected before and after therapy for 16S rRNA gene sequencing. RESULTS: The incidence of gastrointestinal adverse events was lower in probiotics group compared to placebo group (23.6% vs 37.7%, p=0.016), while there was no significant difference in eradication rate. We found dramatic perturbations of gut microbiota immediately following eradication, with the predominance of Proteobacteria in replacement of commensal Firmicutes and Bacteroidetes, and gradually restored after two weeks. The reduction of gut Bacteroidetes caused by eradication drugs was neutralized with probiotics supplementation. The gastric microbiota was completely reconstituted with H. pylori depleted and other taxa flourished. Of note, patients treated with probiotics showed smaller fluctuations of gastric microbiota compared to those with placebo. We also observed changes of saliva microbiota after H. pylori eradication, illustrated by the overgrowth of Neisseria and depletion of Streptococcus. The expansion of some pathogenic genera, including Porphyromonas, Leptotrichia, in the mouth was suppressed by probiotics. CONCLUSION: This study not only demonstrated the beneficial effect of probiotics implementation on side events during H. pylori eradication but also provided a comprehensive profile of microbiome alterations along gastrointestinal tract that modulated by probiotics.
format Online
Article
Text
id pubmed-9679295
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96792952022-11-23 Probiotics modulate gastrointestinal microbiota after Helicobacter pylori eradication: A multicenter randomized double-blind placebo-controlled trial He, Cong Xie, Yong Zhu, Yin Zhuang, Kun Huo, Lijuan Yu, Yong Guo, Qiang Shu, Xu Xiong, Zhijuan Zhang, Zhenyu Lyu, Bin Lu, Nonghua Front Immunol Immunology BACKGROUND: Helicobacter pylori (H. pylori) eradication has been reported to cause short-term disruption of gut microbiota. It is acknowledged that probiotics supplementation mitigates side effects induced by H. pylori eradication, yet its role on alleviating dysbiosis of microbiota is obscure. OBJECTIVES: To evaluate the impact of probiotics on gastrointestinal microbiota after eradication therapy. METHODS: This was a multicenter, double-blinded, randomized trial done at seven centers in China. A total of 276 treatment-naïve H. pylori-positive patients were randomly assigned to receive 14-day bismuth-containing quadruple therapy (esomeprazole, bismuth, amoxicillin, furazolidone) combined with probiotics (Bifidobacterium Tetragenous viable Bacteria Tablets) (n=140) or placebo (n=136) for 28 days. Saliva, gastric mucosa and fecal samples were collected before and after therapy for 16S rRNA gene sequencing. RESULTS: The incidence of gastrointestinal adverse events was lower in probiotics group compared to placebo group (23.6% vs 37.7%, p=0.016), while there was no significant difference in eradication rate. We found dramatic perturbations of gut microbiota immediately following eradication, with the predominance of Proteobacteria in replacement of commensal Firmicutes and Bacteroidetes, and gradually restored after two weeks. The reduction of gut Bacteroidetes caused by eradication drugs was neutralized with probiotics supplementation. The gastric microbiota was completely reconstituted with H. pylori depleted and other taxa flourished. Of note, patients treated with probiotics showed smaller fluctuations of gastric microbiota compared to those with placebo. We also observed changes of saliva microbiota after H. pylori eradication, illustrated by the overgrowth of Neisseria and depletion of Streptococcus. The expansion of some pathogenic genera, including Porphyromonas, Leptotrichia, in the mouth was suppressed by probiotics. CONCLUSION: This study not only demonstrated the beneficial effect of probiotics implementation on side events during H. pylori eradication but also provided a comprehensive profile of microbiome alterations along gastrointestinal tract that modulated by probiotics. Frontiers Media S.A. 2022-11-08 /pmc/articles/PMC9679295/ /pubmed/36426355 http://dx.doi.org/10.3389/fimmu.2022.1033063 Text en Copyright © 2022 He, Xie, Zhu, Zhuang, Huo, Yu, Guo, Shu, Xiong, Zhang, Lyu and Lu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
He, Cong
Xie, Yong
Zhu, Yin
Zhuang, Kun
Huo, Lijuan
Yu, Yong
Guo, Qiang
Shu, Xu
Xiong, Zhijuan
Zhang, Zhenyu
Lyu, Bin
Lu, Nonghua
Probiotics modulate gastrointestinal microbiota after Helicobacter pylori eradication: A multicenter randomized double-blind placebo-controlled trial
title Probiotics modulate gastrointestinal microbiota after Helicobacter pylori eradication: A multicenter randomized double-blind placebo-controlled trial
title_full Probiotics modulate gastrointestinal microbiota after Helicobacter pylori eradication: A multicenter randomized double-blind placebo-controlled trial
title_fullStr Probiotics modulate gastrointestinal microbiota after Helicobacter pylori eradication: A multicenter randomized double-blind placebo-controlled trial
title_full_unstemmed Probiotics modulate gastrointestinal microbiota after Helicobacter pylori eradication: A multicenter randomized double-blind placebo-controlled trial
title_short Probiotics modulate gastrointestinal microbiota after Helicobacter pylori eradication: A multicenter randomized double-blind placebo-controlled trial
title_sort probiotics modulate gastrointestinal microbiota after helicobacter pylori eradication: a multicenter randomized double-blind placebo-controlled trial
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9679295/
https://www.ncbi.nlm.nih.gov/pubmed/36426355
http://dx.doi.org/10.3389/fimmu.2022.1033063
work_keys_str_mv AT hecong probioticsmodulategastrointestinalmicrobiotaafterhelicobacterpylorieradicationamulticenterrandomizeddoubleblindplacebocontrolledtrial
AT xieyong probioticsmodulategastrointestinalmicrobiotaafterhelicobacterpylorieradicationamulticenterrandomizeddoubleblindplacebocontrolledtrial
AT zhuyin probioticsmodulategastrointestinalmicrobiotaafterhelicobacterpylorieradicationamulticenterrandomizeddoubleblindplacebocontrolledtrial
AT zhuangkun probioticsmodulategastrointestinalmicrobiotaafterhelicobacterpylorieradicationamulticenterrandomizeddoubleblindplacebocontrolledtrial
AT huolijuan probioticsmodulategastrointestinalmicrobiotaafterhelicobacterpylorieradicationamulticenterrandomizeddoubleblindplacebocontrolledtrial
AT yuyong probioticsmodulategastrointestinalmicrobiotaafterhelicobacterpylorieradicationamulticenterrandomizeddoubleblindplacebocontrolledtrial
AT guoqiang probioticsmodulategastrointestinalmicrobiotaafterhelicobacterpylorieradicationamulticenterrandomizeddoubleblindplacebocontrolledtrial
AT shuxu probioticsmodulategastrointestinalmicrobiotaafterhelicobacterpylorieradicationamulticenterrandomizeddoubleblindplacebocontrolledtrial
AT xiongzhijuan probioticsmodulategastrointestinalmicrobiotaafterhelicobacterpylorieradicationamulticenterrandomizeddoubleblindplacebocontrolledtrial
AT zhangzhenyu probioticsmodulategastrointestinalmicrobiotaafterhelicobacterpylorieradicationamulticenterrandomizeddoubleblindplacebocontrolledtrial
AT lyubin probioticsmodulategastrointestinalmicrobiotaafterhelicobacterpylorieradicationamulticenterrandomizeddoubleblindplacebocontrolledtrial
AT lunonghua probioticsmodulategastrointestinalmicrobiotaafterhelicobacterpylorieradicationamulticenterrandomizeddoubleblindplacebocontrolledtrial